Showcasing health innovation Dr Séamus O’Neill Chair AHSN Network, CEO AHSN North East and North Cumbria
Our strength lies in our local and national focus A bridge between national impact & local delivery Embedded in our local systems, we can work across sectors to understand & respond to needs A connected network, taking what works locally and spreading nationally A broker between the NHS & industry, and a trusted partner to signpost to solutions
Our continuing mission is to spread healthcare innovation at pace and scale
PReCePT
AF related strokes
ITP – evidencing the AHSNs’ unique value
Economic growth impacts 2018-19 188 £152M 2,605 691 additional investment companies jobs created, jobs leveraged, supported by more than safeguarded £60M above AHSNs our entire 1st our target licence
Partnerships to enhance innovation in reducing the number of AF related strokes Dr Julia Reynolds - Associate Director and Head of Programmes, Innovation Agency (North West Coast AHSN) Dr Quincy Chuka , GPSI Cardiology and Clinical Lead LTC, NHS Warrington CCG #AHSNs @AHSNNetwork
More people to find in the North West Coast • 108,875 people expected to have AF yet only 93,446 are on the register • 15,429 undiagnosed people potentially not getting Detect appropriate treatment • 13,120 diagnosed people are not being treated with Protect anticoagulants • The proportion of patients on each GP register with undetected AF varies across the CCGs
Detect initiatives in 2018… case finding with mobile ECGs Fire & Rescue Services AF Ambassadors 1,595 tested 69 Possible AFs Public campaigns 1,346 tested 18 possible AFs GP practices over 300 devices to GPs Morecambe, East Lancashire, Blackburn with Darwen, Blackpool, Fylde & Wyre, Warrington, Liverpool, Wirral
68 The Innovation Agency response: practices The NWC Atrial Fibrillation Collaborative across 4 CCGs Practices worked to generate and over a through a driver improvement 9 month project change diagram goals ideas Protect AIMS To have 80% of all Detect To close the prevalence gap between observed AF high risk AF patients prevalence and the expected (CHADS2S-VASc>1) on AF prevalence by 50% anticoagulation therapy Practice support included Quality Improvement Kardia mobile AF clinical Case-finding GRASP-AF (QI) training and ECG devices training and support training support materials
26 Warrington CCG’S Atrial Fibrillation practices across Collaborative: Sustainable approach Population ~220 000 Improve clinician’s -AF pathways 2 hour clinical 18 month project confidence - Templates session per practice Capacity -85% of all GPs Reduce variation between AIM practices of Prevalence and - 95% of all practice anticoagulation of AF patients pharmacists - 60% of all Nurses/ HCAs Practice support included Quality Improvement Kardia mobile AF clinical GRASP-AF Incentive (QI) training and ECG devices training and training -£1500 support materials -DS & Pfizer
Warrington CCG’S Atrial Fibrillation Collaborative THE RESULTS THE IMPACT This initiative led to an estimated… 794 Detect 27.6 strokes saved patients added to per year AF registers based on one stroke per 25 people not anticoagulated 690 Protect Savings to the £480,000 health system high risk AF patients initiated in year one alone on anticoagulation therapy Savings over 5 Years Societal Cost Savings over 5 Years £2,400,030 £13.1 M
PReCePT: protecting preterm babies from cerebral palsy Dr Karen Luyt , Consultant Neonatologist, University Hospitals Bristol Natasha Swinscoe , CEO, West of England AHSN #AHSNs @AHSNNetwork
The birth of PReCePT Gloucestershire Hospital • 6 month quality improvement (QI) project with rapid success • Increase in uptake in magnesium sulphate in all 5 units (81 – 100% use in eligible women) • Of 82 eligible births, 72 women received the intervention (88% overall compliance) • Practice embedded and sustained Southmead Hospital Great Western Hospital St Michael’s Hospital Royal United Hospitals Bath
PReCePT programme overview Network approach 2016 June 2018 Sep 2018 • £1 million Delivered via the • funding AHSNs Standardised • resources 90 hours midwife • backfill per unit Regional clinical lead • Target: 85% of • eligible mothers receive MgSO4 by March 2020
PReCePT programme: progress so far • 121 maternity trusts • 79.5% uptake of MgSO4
PReCePT programme: progress so far
PReCePT programme: progress so far PReCePT is endorsed by… and features in…
Find out more: www.ahsnnetwork/PReCePT Follow us on Twitter: Programme: @PReCePT_MgSO4 Study: @PReCePT_study
EMAHSN and Qbtech Transforming ADHD Care in the East Midlands Tony Doyle Managing Director, Qbtech Ltd #AHSNs @AHSNNetwork
Improving diagnosis of ADHD in children ADHD – Commonly occurring, severely QbTest – Digital test of sustained attention impairing, yet very responsive to treatment with motion capture to measure core indicator symptoms of ADHD • Chronic neurodevelopmental disorder affecting 5% of children • The only CE marked, European Medicines Agency (EMA) registered and Food and Drug • Most cases diagnosed in 6-12 years olds – ten Administration (FDA) cleared intervention that fold increase since 1980s simultaneously measures: • Characterised by a persistent pattern of Attention, impulsivity and motor activity, the inattention and/or hyperactivity and impulsivity core requirements of diagnostic criteria in • Can lead to; poor educational progress, both DSMIV and ICD10 accidents, poor employability, sleep and anxiety • Performance is compared to an age and gender disorders, a range of social issues and reliance matched normative control group on health and social care • Provides objective, quality, unbiased information • Costs the NHS at least £23m each year in specialist assessments to inform diagnosis • Cuts through ambiguity, standardises clinical practice, measures effectiveness of treatment
Family and clinician experience of ADHD
QbTest
Outcomes • Time from assessment to diagnosis reduced by 153 days • Released 20% clinical workforce time • Cost reductions (efficiency) of 32.6% / ROI = £84,460 • 85% of patients found the QbTest results helpful • 94% of clinicians reported greater understanding of patients symptoms • QbTest sustainability in all three Trusts beyond funded demonstrator • 41 Trusts currently deploying QbTests across 73 sites in England
EMAHSN support Funding of 12 month ‘real world’ demonstrator in three Trusts across six sites in the East Midlands. But just as important: Metrics – evaluation • Accountability and monitoring – steering group • Capacity / resource – project manager and boots on the ground • Independent evaluation – different pathway models • Credibility – NHS leverage • Adoption and spread – stakeholder mapping / ongoing partnership • Communications – high quality targeted comms •
For more information please contact: Dara Coppel EMAHSN, Head of Innovation Programme Delivery 07917 220 140 l dara.coppel@nottingham.ac.uk Tony Doyle Qbtech Limited, Managing Director 07771 937 845 www.qbtech.com | @QbtechADHD www.emahsn.org.uk | @EM_AHSN
Digital Transformation of Continuing Healthcare Charles MacKinnon NIA Fellow Healthcare Director IEG4 Ltd #AHSNs @AHSNNetwork
National Improvement Priority • DToC Focus • NAO report • Digital a key enabler
Collaboration, collaboration… repeat • Content Lead NHS Cohort • Abc • Xyz Fast Followers Increasing Involvement
Digital CHC Streamlined Workflow With no paperwork Simple Back Office With intuitive functions
NHS Innovation Assurance A high-scoring, eminently usable system that greatly impressed all of our assessors in terms especially of clinical efficacy , safety, security and privacy. OurMobileHealth.com Digital Service Assessors for NHS ITP identifies and Encourages NHS To Adopt Proven Innovations IEG4’s CHC2DST 1 of 10 finalists Innovation & Technology Payment Programme
Health and Care Innovation Adoption Promoting the “it’s a contact sport”! Funding and managing independent evaluation Following the adoption at scale model for GM
Panel Q&A #AHSNs @AHSNNetwork
Dr Séamus O’Neill - Chair AHSN Network, CEO AHSN North East and North Cumbria Dr Julia Reynolds - Associate Director and Head of Programmes, Innovation Agency Dr Quincy Chuka - GPSI Cardiology and Clinical Lead Long Term Conditions, NHS Warrington CCG Dr Karen Luyt - Consultant Neonatologist, University Hospitals Bristol Natasha Swinscoe - CEO, West of England AHSN Tony Doyle - Managing Director, Qbtech Ltd Charles MacKinnon - NIA Fellow and Healthcare Director IEG4 Ltd #AHSNs @AHSNNetwork
Recommend
More recommend
